Thursday, 23 September 2021

Webinar - Watch On Demand

Why Oncology Biotechs are Choosing Australia and Avance Clinical for their Trials

Date: 02nd June 2020 Time: 02:30 PM (Singapore Time)

Why Oncology Biotechs are Choosing Australia and Avance Clinical for their Trials

Australia offers significant early phase advantages with attractive models around speed, efficiency, and cost. However, as oncology studies become increasingly complex, working with the right CRO is even more vital for success.

In this webinar, we’ll discuss the many advantages of moving your early phase trials to Australia including:

  • Almost 50% lower cost,
  • Attractive regulatory environment for rapid trial approvals
  • Internationally regarded for quality science
  • World-leading investigators and KOLs
  • Phase 1 units and most sites open during COVID-19 crisis

  Watch Now:


Gabriel Kremmidiotis
PhD, BSC Hon
Chief Scientific Officer

About Gabriel :

Gabriel has 26 years’ experience in medical research and drug development. He has devoted most of his career to the biotechnology industry, managing drug development programs from early discovery to completion of phase II proof of concept clinical trials and subsequent commercial drug licensing deals.
He has been part of the CPR Pharma Services team since 2015 managing the department of clinical operations and offering drug development advice to biotechnology companies seeking to enter clinical trials in Australia. In 2019, Gabriel was appointed Chief Scientific Officer of Avance Clinical where he currently leads the Department of Scientific and Medical affairs offering Medical Writing, Drug safety monitoring and reporting and early phase clinical drug development and regulatory advice services.

Prior to joining CPR Pharma Services, Gabriel was the Vice President Research & Development of the Australian ASX listed company Bionomics limited where over several years led teams in discovery and progression of cancer therapeutics through to completion of several phase I and Phase II clinical trials in Australia and the US.
Gabriel’s 26 years in medical research also includes appointments with the Cancer Therapeutics CRC, Flinders University of South Australia, Adelaide University, the Los Alamos National Laboratories and the Adelaide Women’s and Children’s Hospital.
With primary expertise in oncology, Gabriel has a diverse scientific background spanning the fields of Clinical Development, Drug Discovery, Cancer Biology, Molecular Genetics, Bioinformatics and Immunology. He has a PhD and a Bachelor of Science (Honours) from Flinders University and a Bachelor of Science from The University of Melbourne. He has published research findings in 29 international scientific papers and has several patent inventions on cancer genes and small molecule anti-cancer therapeutics. Gabriel is a member of the American Association for Cancer Research, the American Society of Clinical Oncology and ARCS Australia.